How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,864 results for

Osteosarcoma

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Highly expressed ribosomal protein L34 indicates poor prognosis in osteosarcoma and its knockdown suppresses osteosarcoma proliferation probably through translational control (PubMed)

Highly expressed ribosomal protein L34 indicates poor prognosis in osteosarcoma and its knockdown suppresses osteosarcoma proliferation probably through translational control Osteosarcoma has devastating health implications on children and adolescents. However, due to its low incidence and high tumor heterogeneity, it is hard to achieve any further improvements in therapy and overall survival. Ribosomal protein L34 (RPL34) has been increasingly recognized to promote the proliferation (...) of malignant cells, but its role in osteosarcoma has not been investigated. In this study, real-time quantitative PCR (RT-qPCR) and immunohistochemistry revealed that RPL34 was highly expressed in osteosarcoma tissues when compared to adjacent tissues and normal bone tissues. Survival analysis showed that high expression of RPL34 predicted a poor prognosis for osteosarcoma patients. Knockdown of RPL34 in Saos-2 cells via lentivirus-mediated small interfering RNA (siRNA) significantly inhibited cell

Full Text available with Trip Pro

2016 Scientific reports

42. Bone morphogenetic protein-2 promotes osteosarcoma growth by promoting epithelial-mesenchymal transition (EMT) through the Wnt/β-catenin signaling pathway. (PubMed)

Bone morphogenetic protein-2 promotes osteosarcoma growth by promoting epithelial-mesenchymal transition (EMT) through the Wnt/β-catenin signaling pathway. The correlation between BMP-2 and osteosarcoma growth has gained increased interest in the recent years, however, there is still no consensus. In this study, we tested the effects of BMP-2 on osteosarcoma cells through both in vitro and in vivo experiments. The effect of BMP-2 on the proliferation, migration and invasion of osteosarcoma (...) cells was tested in vitro. Subcutaneous and intratibial tumor models were used for the in vivo experiments in nude mice. The effects of BMP-2 on EMT of osteosarcoma cells and the Wnt/β-catenin signaling pathway were also tested using a variety of biochemical methods. In vitro tests did not show a significant effect of BMP-2 on tumor cell proliferation. However, BMP-2 increased the mobility of tumor cells and the invasion assay demonstrated that BMP-2 promoted invasion of osteosarcoma cells in vitro

2019 Journal of Orthopaedic Research

43. Behavioral therapy for acute post-surgical phantom limb pain in a young adult with osteosarcoma. (PubMed)

Behavioral therapy for acute post-surgical phantom limb pain in a young adult with osteosarcoma. 30681260 2019 03 12 1533-2500 2019 Jan 25 Pain practice : the official journal of World Institute of Pain Pain Pract Behavioral Therapy for Acute Post-Surgical Phantom Limb Pain in a Young Adult With Osteosarcoma. 10.1111/papr.12768 Wong Shan S SS https://orcid.org/0000-0002-5203-2704 Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina, U.S.A

2019 Pain Practice

44. A case report of primary osteosarcoma originating from kidney. (PubMed)

A case report of primary osteosarcoma originating from kidney. Primary osteosarcoma of the kidney is a very rare subtype of renal neoplasms. There are only 27 cases reported in the literature since 1936. In addition, it has a high risk of metastasis and very low survival rate.In this report, we present a case of unique large osteosarcoma originated from the left kidney (21 cm × 18 cm × 11 cm) with lung metastasis. A 48-year-old female patient presented with intermittent abdominal distension (...) patient was followed up for 26 months, with no postoperative complications, no tumor recurrence, and no progress in pulmonary metastasis.The case reported here is a unique large osteosarcoma originated from the kidney (21 cm × 18 cm × 11 cm) at an advanced stage (IV). However, the patient's condition was controlled for at least 26 months after surgical resection and postoperative chemotherapy, which had never been reported in the literature before. Additionally, 3 mutated genes were found

2019 Medicine

45. CYR61 triggers osteosarcoma metastatic spreading via an IGF1Rβ-dependent EMT-like process. (PubMed)

CYR61 triggers osteosarcoma metastatic spreading via an IGF1Rβ-dependent EMT-like process. Osteosarcoma is the most prevalent primary bone malignancy in children and young adults. These tumors are highly metastatic, leading to poor outcome. We previously demonstrated that Cysteine-rich protein 61 (CYR61/CCN1) expression level is correlated to osteosarcoma aggressiveness in preclinical model and in patient tumor samples. The aim of the present study was to investigate the CYR61-induced (...) intracellular mechanisms leading to the acquisition of an invasive phenotype by osteosarcoma cells.Modified murine and human osteosarcoma cell lines were evaluated for cell adhesion, aggregation (spheroid), motility (wound healing assay), phenotypic markers expression (RT-qPCR, western blot). Cell-derived xenograft FFPE samples and patients samples (TMA) were assessed by IHC.CYR61 levels controlled the expression of markers related to an Epithelial-mesenchymal transition (EMT)-like process, allowing tumor

Full Text available with Trip Pro

2019 BMC Cancer

46. Parosteal osteosarcoma of the fibula in a middle-aged patient: A case report. (PubMed)

Parosteal osteosarcoma of the fibula in a middle-aged patient: A case report. Parosteal osteosarcoma (PO) is relatively rare, accounting for about 1% of primary malignant bone tumors and 4% of all osteosarcomas. Onset is generally at approximately 20 to 40 years of age; the distal posterior surface of femur is the most common site, accounting for more than 60% cases. However, PO in middle-aged or elderly patients is extremely rare and PO occurring in the fibula is even rarer. To our knowledge

2019 Medicine

47. Interleukin-35 suppresses antitumor activity of circulating CD8<sup>+</sup> T cells in osteosarcoma patients. (PubMed)

Interleukin-35 suppresses antitumor activity of circulating CD8+ T cells in osteosarcoma patients. Purpose/Aim of the study: Interleukin (IL)-35 is a newly identified IL-12 cytokine family member and reveals immunosuppressive activity to CD8+ T cells in inflammation, infectious diseases, and cancers. However, little is known regarding IL-35 function in osteosarcoma. Thus, the aim of the current study was to investigate the regulatory function of IL-35 to CD8+ T cells (...) in osteosarcoma.Thirty-five osteosarcoma patients and 20 healthy individuals were enrolled. Serum CD4+CD25+CD127dim/- regulatory T cells (Tregs) and CD8+ T cells were purified. IL-35 concentration in serum and cultured supernatants was measured by enzyme-linked immunosorbent assay. Osteosarcoma cell line MG-63 cells and CD8+ T cells were stimulated with recombinant IL-35 in vitro, and modulatory function of IL-35 on these cells was assessed by investigation of cellular proliferation, cell cycle, apoptosis

2019 Connective Tissue Research

48. Prognosis of osteosarcomas in the mandible: 15-year experience of 55 patients. (PubMed)

Prognosis of osteosarcomas in the mandible: 15-year experience of 55 patients. Our goal was to evaluate the prognosis of osteosarcomas (OS) in the mandible for finding out the best treatment.Patients diagnosed with OS in the mandible from January 2000 to December 2015 were retrospectively enrolled. Demographic, tumor-specific, treatment, and survival data were collected and analyzed.A total of 55 patients (35 male and 20 female) were included, all patients had first manifestation of swelling

2019 Medicine

49. A genetically engineered microRNA-34a prodrug demonstrates anti-tumor activity in a canine model of osteosarcoma. (PubMed)

A genetically engineered microRNA-34a prodrug demonstrates anti-tumor activity in a canine model of osteosarcoma. Osteosarcoma (OSA) represents the most common primary bone tumor in humans and pet dogs. Little progress has been made with regard to viable treatment options in the past three decades and patients presenting with metastatic disease continue to have a poor prognosis. Recent mouse studies have suggested that microRNA-34a (miR-34a) may have anti-tumor activities in human OSA models

Full Text available with Trip Pro

2018 PLoS ONE

50. Resveratrol eliminates cancer stem cells of osteosarcoma by STAT3 pathway inhibition. (PubMed)

Resveratrol eliminates cancer stem cells of osteosarcoma by STAT3 pathway inhibition. Resveratrol shows potent anti-tumor therapeutic properties in various tumors. However, the exact effect of resveratrol on osteosarcoma cells, especially cancer stem cells, remains unclear. In this study, we examined the effect of resveratrol on osteosarcoma stem cells and explored the underlying molecular mechanisms. Resveratrol inhibited cell viability, self-renewal ability and tumorigenesis of osteosarcoma (...) cells, whereas showed no significant inhibition effects to normal osteoblast cells. Mechanically, resveratrol treatment decreased cytokines synthesis and inhibited JAK2/STAT3 signaling, which was consistent with the decline of cancer stem cells marker, CD133. Exogenous STAT3 activation attenuated the cancer stem cell elimination effects of resveratrol treatment. Our results demonstrated that resveratrol inhibited osteosarcoma cell proliferation and tumorigenesis ability, which was correlated

Full Text available with Trip Pro

2018 PLoS ONE

51. MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. (PubMed)

MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. Osteosarcoma (OSA) is the most common bone tumor in children and dogs; however, no substantial improvement in clinical outcome has occurred in either species over the past 30 years. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and play a fundamental role in cancer. The purpose of this study was to investigate the potential contribution of miR-34a loss to the biology of canine OSA, a well

Full Text available with Trip Pro

2018 PLoS ONE

52. Atypical "Sclerosing" Osteoblastic Neoplasm: A Tumor of Intermediate Biological Potential Between Usual Osteoblastoma and Conventional Osteosarcoma. (PubMed)

Atypical "Sclerosing" Osteoblastic Neoplasm: A Tumor of Intermediate Biological Potential Between Usual Osteoblastoma and Conventional Osteosarcoma. The existence of "aggressive" osteoblastoma (OB) or malignant transformation of OB is controversial. Over a few decades, we have encountered a group of "borderline" sclerosing osteoblastic lesions that are difficult to classify, tending toward local recurrence, especially following curettage. A search of the consultative and institutional files (...) from 3 co-authors for atypical OB, malignant transformation of OB, well-differentiated osteosarcoma (OS), and OB-like OS diagnoses revealed 8 similar cases. There were 6 males and 2 females, ages 11 to 55 years (mean, 26 y). Three arose in metatarsals, 2 in the fibula, and 1 each in the humerus, tibia, and femur. Radiologically, most were expansile, lytic to sclerotic, with circumscribed and at least partially sclerotic borders. Pathologically, all displayed a predominant, sclerosing sheet-like

2019 American Journal of Surgical Pathology

53. Tegavivint and the β-catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma. (PubMed)

Tegavivint and the β-catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma. The Wnt/β-catenin pathway is closely associated with osteosarcoma (OS) development and metastatic progression. We investigated the antitumor activity of Tegavivint, a novel β-catenin/transducing β-like protein 1 (TBL1) inhibitor, against OS employing in vitro, ex vivo and in vivo cell line and patient-derived xenograft (PDX) models that recapitulate high risk disease.The antitumor efficacy

Full Text available with Trip Pro

2019 Journal of the National Cancer Institute

54. Autocrine production of reproductive axis neuropeptides affects proliferation of canine osteosarcoma in vitro. (PubMed)

Autocrine production of reproductive axis neuropeptides affects proliferation of canine osteosarcoma in vitro. Osteosarcoma strikes hundreds of people each year, of both advanced and younger ages, and is often terminal. Like many tumor types, these bone tumors will frequently undergo a neuroendocrine transition, utilizing autocrine and/or paracrine hormones as growth factors and/or promoters of angiogenesis to facilitate progression and metastasis. While many of these factors and their actions (...) on tumor growth are characterized, some tumor-derived neuropeptides remain unexplored.Using validated canine osteosarcoma cell lines in vitro, as well as cells derived from spontaneous tumors in dogs, we explored the autocrine production of two neuropeptides typically found in the hypothalamus, and most closely associated with reproduction: gonadotropin-releasing hormone (GnRH) and kisspeptin (Kiss-1). We evaluated gene expression and protein secretion of these hormones using quantitative RT-PCR

Full Text available with Trip Pro

2019 BMC Cancer

55. Novel near-infrared fluorescence-guided surgery with vesicular stomatitis virus for complete surgical resection of osteosarcomas in mice. (PubMed)

Novel near-infrared fluorescence-guided surgery with vesicular stomatitis virus for complete surgical resection of osteosarcomas in mice. Attempts have been made to visualize tumor cells intraoperatively with fluorescence guidance. However, the clear demarcation and complete tumor resection have always been a challenging task. To address this, we have developed a novel fluorescence bioimaging system with vesicular stomatitis virus (VSV) incorporating Katushka, near-infrared fluorescent protein (...) . VSV is tumor-specific owing to the deficiency of antiviral interferon signaling pathways in tumor cells. We aimed to evaluate the tumor specificity of the recombinant VSV-Katushka (rVSV-K) in osteosarcoma cells and to assess the feasibility of complete tumor resection by the rVSV-K fluorescence guidance. In in vitro experiments, mouse and human osteosarcoma cell lines and normal human mesenchymal stem cells were infected with rVSV-K and observed by fluorescence microscopy. Near-infrared

2019 Journal of Orthopaedic Research

56. Circular RNAs hsa_circ_0032462, hsa_circ_0028173, hsa_circ_0005909 are predicted to promote CADM1 expression by functioning as miRNAs sponge in human osteosarcoma. (PubMed)

Circular RNAs hsa_circ_0032462, hsa_circ_0028173, hsa_circ_0005909 are predicted to promote CADM1 expression by functioning as miRNAs sponge in human osteosarcoma. Osteosarcoma (OS) is a primary malignant bone tumor with a high fatality rate. Many circRNAs have been proved to play important roles in the pathogenesis of some diseases. However, the occurrence of circRNAs in OS remains little known.The circular RNA (circRNA) expression file GSE96964 dataset, which included seven osteosarcoma cell (...) lines and one control sample (osteoblast cell line), was downloaded from the Gene Expression Omnibus (GEO) database to explore the potential function of circRNAs in osteosarcoma by competing endogenous RNA (ceRNA) analysis. Three gene expression profiles of OS were downloaded from GEO database and then used for the pathway enrichment analysis, Venn analysis and protein-protein interaction (PPI) network analysis. Real-time qPCR validation and RNA interference were conducted to verify our

Full Text available with Trip Pro

2018 PLoS ONE

57. Alpha particle Radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial. (PubMed)

Alpha particle Radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial. The prognosis of metastatic osteosarcoma continues to be poor. We hypothesized that alpha-emitting, bone-targeting radium 223 dichloride (223RaCl2) can be safely administered to patients with osteosarcoma and that early signals of response or resistance can be assessed by quantitative and qualitative correlative imaging studies and biomarkers.A 3+3 phase I, dose-escalation trial of 223RaCl2 (50, 75 (...) , and 100 kBq/kg) was designed in recurrent/metastatic osteosarcoma patients aged ≥15 years. Objective measurements included changes in SUV of PET (18FDG and/or NaF-18) and single-photon-emission-computed-tomography-computed tomography (99mTc-MDP) as well as alkaline phosphatase and bone turnover markers at baseline, mid-study, and the end of the study.Among 18 patients enrolled (including 15 males) aged 15-71 years, tumor locations included spine (n=12, 67%), pelvis (n=10, 56%), ribs (n=9, 50

Full Text available with Trip Pro

2019 Clinical Cancer Research

58. Integrative analysis reveals driver long non-coding RNAs in osteosarcoma. (PubMed)

Integrative analysis reveals driver long non-coding RNAs in osteosarcoma. Transcriptome profiling of osteosarcoma (OS) by next generation sequencing technology (NGS) has been broadly performed by previous researches, which uncovers a large number protein-coding driver genes, facilitates our understanding of the molecular mechanisms of OS formation, progression and metastasis. Recently, more and more researchers realize the importance of long non-coding RNAs (lncRNAs) on the development of OS

2019 Medicine

59. Efficacy of methotrexate, doxorubicin, and cisplatin for osteosarcoma: Study protocol for a systematic review of randomized controlled trial. (PubMed)

Efficacy of methotrexate, doxorubicin, and cisplatin for osteosarcoma: Study protocol for a systematic review of randomized controlled trial. This systematic review will address the efficacy and safety of methotrexate, doxorubicin, and cisplatin (MAP) for the treatment of patients with osteosarcoma.We will retrieve the studies from the following 9 electronic databases: Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE, the Cumulative Index to Nursing and Allied Health Literature (...) of patients with osteosarcoma. The primary outcome includes event-free survival. The secondary outcomes consist of overall survival, quality of life, and toxicity. In addition, 2 independent researchers will extract data, and will assess the quality of included studies by using Cochrane risk of bias tool. Results data will be pooled and meta-analysis will be conducted if >2 eligible studies will be included.This systematic review will evaluate the efficacy and safety of MAP for the treatment of patients

Full Text available with Trip Pro

2019 Medicine

60. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma. (PubMed)

Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma. Mutant TP53 is a promising therapeutic target in cancers. Considering the current challenges facing the clinical treatment of cancer, as well as the urgent need to identify novel therapeutic targets in osteosarcomas, we aimed to evaluate the clinical significance of mutant TP53 in osteosarcoma patients and to explore the therapeutic effect of targeting mutant TP53 in osteosarcomas. We performed a meta (...) -analysis to investigate the relationship between mutant TP53 and the overall survival of patients with osteosarcoma. A CRISPR-Cas9 system and a TP53 inhibitor, NSC59984, were also used to specifically knock-out and inhibit mutant TP53 in the human osteosarcoma cell lines, KHOS, and KHOSR2. The meta-analysis demonstrated that mutations in the TP53 gene could be used to predict a poor 2-year survival in osteosarcoma patients. We also demonstrated that the expression of mutant TP53 in human osteosarcoma

2019 Journal of Orthopaedic Research

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>